Cargando…

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients

Chronic kidney disease (CKD) patients may be more susceptible to adverse drug reactions (ADRs), given their complex medication regimen and altered physiological state driven by a decline in kidney function. This study aimed to describe the relationship between CYP3A5*3 polymorphism and the ADR of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Fei Yee, Islahudin, Farida, Abdul Gafor, Abdul Halim, Wong, Hin-Seng, Bavanandan, Sunita, Mohd Saffian, Shamin, Md Redzuan, Adyani, Makmor-Bakry, Mohd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963814/
https://www.ncbi.nlm.nih.gov/pubmed/35359836
http://dx.doi.org/10.3389/fphar.2022.848804
_version_ 1784678070458777600
author Lee, Fei Yee
Islahudin, Farida
Abdul Gafor, Abdul Halim
Wong, Hin-Seng
Bavanandan, Sunita
Mohd Saffian, Shamin
Md Redzuan, Adyani
Makmor-Bakry, Mohd
author_facet Lee, Fei Yee
Islahudin, Farida
Abdul Gafor, Abdul Halim
Wong, Hin-Seng
Bavanandan, Sunita
Mohd Saffian, Shamin
Md Redzuan, Adyani
Makmor-Bakry, Mohd
author_sort Lee, Fei Yee
collection PubMed
description Chronic kidney disease (CKD) patients may be more susceptible to adverse drug reactions (ADRs), given their complex medication regimen and altered physiological state driven by a decline in kidney function. This study aimed to describe the relationship between CYP3A5*3 polymorphism and the ADR of antihypertensive drugs in CKD patients. This retrospective, multi-center, observational cohort study was performed among adult CKD patients with a follow-up period of up to 3 years. ADRs were detected through medical records. CYP3A5*3 genotyping was performed using the direct sequencing method. From the 200 patients recruited in this study, 33 (16.5%) were found to have ADRs related to antihypertensive drugs, with 40 ADRs reported. The most frequent ADR recorded was hyperkalemia (n = 8, 20.0%), followed by bradycardia, hypotension, and dizziness, with 6 cases (15.0%) each. The most common suspected agents were angiotensin II receptor blockers (n = 11, 27.5%), followed by angiotensin-converting enzyme inhibitors (n = 9, 22.5%). The CYP3A5*3 polymorphism was not found to be associated with antihypertensive-related ADR across the genetic models tested, despite adjustment for other possible factors through multiple logistic regression (p > 0.05). After adjusting for possible confounding factors, the factors associated with antihypertensive-related ADR were anemia (adjusted odds ratio [aOR] 5.438, 95% confidence interval [CI]: 2.002, 14.288) and poor medication adherence (aOR 3.512, 95% CI: 1.470, 8.388). In conclusion, the CYP3A5*3 polymorphism was not found to be associated with ADRs related to antihypertensives in CKD patients, which requires further verification by larger studies.
format Online
Article
Text
id pubmed-8963814
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89638142022-03-30 Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients Lee, Fei Yee Islahudin, Farida Abdul Gafor, Abdul Halim Wong, Hin-Seng Bavanandan, Sunita Mohd Saffian, Shamin Md Redzuan, Adyani Makmor-Bakry, Mohd Front Pharmacol Pharmacology Chronic kidney disease (CKD) patients may be more susceptible to adverse drug reactions (ADRs), given their complex medication regimen and altered physiological state driven by a decline in kidney function. This study aimed to describe the relationship between CYP3A5*3 polymorphism and the ADR of antihypertensive drugs in CKD patients. This retrospective, multi-center, observational cohort study was performed among adult CKD patients with a follow-up period of up to 3 years. ADRs were detected through medical records. CYP3A5*3 genotyping was performed using the direct sequencing method. From the 200 patients recruited in this study, 33 (16.5%) were found to have ADRs related to antihypertensive drugs, with 40 ADRs reported. The most frequent ADR recorded was hyperkalemia (n = 8, 20.0%), followed by bradycardia, hypotension, and dizziness, with 6 cases (15.0%) each. The most common suspected agents were angiotensin II receptor blockers (n = 11, 27.5%), followed by angiotensin-converting enzyme inhibitors (n = 9, 22.5%). The CYP3A5*3 polymorphism was not found to be associated with antihypertensive-related ADR across the genetic models tested, despite adjustment for other possible factors through multiple logistic regression (p > 0.05). After adjusting for possible confounding factors, the factors associated with antihypertensive-related ADR were anemia (adjusted odds ratio [aOR] 5.438, 95% confidence interval [CI]: 2.002, 14.288) and poor medication adherence (aOR 3.512, 95% CI: 1.470, 8.388). In conclusion, the CYP3A5*3 polymorphism was not found to be associated with ADRs related to antihypertensives in CKD patients, which requires further verification by larger studies. Frontiers Media S.A. 2022-03-14 /pmc/articles/PMC8963814/ /pubmed/35359836 http://dx.doi.org/10.3389/fphar.2022.848804 Text en Copyright © 2022 Lee, Islahudin, Abdul Gafor, Wong, Bavanandan, Mohd Saffian, Md Redzuan and Makmor-Bakry. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lee, Fei Yee
Islahudin, Farida
Abdul Gafor, Abdul Halim
Wong, Hin-Seng
Bavanandan, Sunita
Mohd Saffian, Shamin
Md Redzuan, Adyani
Makmor-Bakry, Mohd
Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
title Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
title_full Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
title_fullStr Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
title_full_unstemmed Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
title_short Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
title_sort adverse drug reactions of antihypertensives and cyp3a5*3 polymorphism among chronic kidney disease patients
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963814/
https://www.ncbi.nlm.nih.gov/pubmed/35359836
http://dx.doi.org/10.3389/fphar.2022.848804
work_keys_str_mv AT leefeiyee adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT islahudinfarida adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT abdulgaforabdulhalim adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT wonghinseng adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT bavanandansunita adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT mohdsaffianshamin adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT mdredzuanadyani adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients
AT makmorbakrymohd adversedrugreactionsofantihypertensivesandcyp3a53polymorphismamongchronickidneydiseasepatients